Log in
Enquire now
Noema Pharma

Noema Pharma

Treatment developer for central nervous system (CNS) disorders patient.

OverviewStructured DataIssuesContributors

Contents

noemapharma.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Biotechnology
Biotechnology
Health technology
Health technology
Pharmaceutical industry
Pharmaceutical industry
Biomedical engineering
Biomedical engineering
Location
Switzerland
Switzerland
B2X
B2B
B2B
CEO
‌
Ilise Lombardo
Pitchbook URL
pitchbook.com/profiles...454524-94
Number of Employees (Ranges)
11 – 50
Email Address
info@noemapharma.com
Investors
EQT Life Sciences
EQT Life Sciences
Forbion Capital Partners
Forbion Capital Partners
BioMedPartners
BioMedPartners
Jeito Capital
Jeito Capital
UPMC Enterprises
UPMC Enterprises
Gilde Healthcare
Gilde Healthcare
Invus
Invus
Sofinnova Partners
Sofinnova Partners
...
Founded Date
January 1, 2019
Total Funding Amount (USD)
317,000,000
Latest Funding Round Date
December 13, 2024
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Country
Switzerland
Switzerland
Headquarters
Basel
Basel

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
147,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Noema Pharma

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.